Autologous stromal vascular fraction therapy for rheumatoid arthritis

Rationale and clinical safety

Jorge Paz Rodriguez, Michael P. Murphy, Soon Jun Hong, Marialaura Madrigal, Keith L. March, Boris Minev, Robert J. Harman, Chien Shing Chen, Ruben Berrocal Timmons, Annette M. Marleau, Neil H. Riordan

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

Original languageEnglish
Article number5
JournalInternational Archives of Medicine
Volume5
Issue number1
DOIs
Publication statusPublished - 2012 Mar 14
Externally publishedYes

Fingerprint

Blood Vessels
Rheumatoid Arthritis
Safety
Biological Therapy
Veterinary Medicine
Therapeutics
Clinical Protocols
Cell- and Tissue-Based Therapy
Stem Cells
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Autologous stromal vascular fraction therapy for rheumatoid arthritis : Rationale and clinical safety. / Rodriguez, Jorge Paz; Murphy, Michael P.; Hong, Soon Jun; Madrigal, Marialaura; March, Keith L.; Minev, Boris; Harman, Robert J.; Chen, Chien Shing; Timmons, Ruben Berrocal; Marleau, Annette M.; Riordan, Neil H.

In: International Archives of Medicine, Vol. 5, No. 1, 5, 14.03.2012.

Research output: Contribution to journalReview article

Rodriguez, JP, Murphy, MP, Hong, SJ, Madrigal, M, March, KL, Minev, B, Harman, RJ, Chen, CS, Timmons, RB, Marleau, AM & Riordan, NH 2012, 'Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety', International Archives of Medicine, vol. 5, no. 1, 5. https://doi.org/10.1186/1755-7682-5-522313603
Rodriguez, Jorge Paz ; Murphy, Michael P. ; Hong, Soon Jun ; Madrigal, Marialaura ; March, Keith L. ; Minev, Boris ; Harman, Robert J. ; Chen, Chien Shing ; Timmons, Ruben Berrocal ; Marleau, Annette M. ; Riordan, Neil H. / Autologous stromal vascular fraction therapy for rheumatoid arthritis : Rationale and clinical safety. In: International Archives of Medicine. 2012 ; Vol. 5, No. 1.
@article{f5acc76083d649209cc1cec5b17cd25b,
title = "Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety",
abstract = "Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50{\%} of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80{\%} improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.",
author = "Rodriguez, {Jorge Paz} and Murphy, {Michael P.} and Hong, {Soon Jun} and Marialaura Madrigal and March, {Keith L.} and Boris Minev and Harman, {Robert J.} and Chen, {Chien Shing} and Timmons, {Ruben Berrocal} and Marleau, {Annette M.} and Riordan, {Neil H.}",
year = "2012",
month = "3",
day = "14",
doi = "10.1186/1755-7682-5-522313603",
language = "English",
volume = "5",
journal = "International Archives of Medicine",
issn = "1755-7682",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Autologous stromal vascular fraction therapy for rheumatoid arthritis

T2 - Rationale and clinical safety

AU - Rodriguez, Jorge Paz

AU - Murphy, Michael P.

AU - Hong, Soon Jun

AU - Madrigal, Marialaura

AU - March, Keith L.

AU - Minev, Boris

AU - Harman, Robert J.

AU - Chen, Chien Shing

AU - Timmons, Ruben Berrocal

AU - Marleau, Annette M.

AU - Riordan, Neil H.

PY - 2012/3/14

Y1 - 2012/3/14

N2 - Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

AB - Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

UR - http://www.scopus.com/inward/record.url?scp=84863295482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863295482&partnerID=8YFLogxK

U2 - 10.1186/1755-7682-5-522313603

DO - 10.1186/1755-7682-5-522313603

M3 - Review article

VL - 5

JO - International Archives of Medicine

JF - International Archives of Medicine

SN - 1755-7682

IS - 1

M1 - 5

ER -